Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital;Suscetibilidade a antifúngicos de variedades de Cryptococcus neoformans isoladas de pacientes em hospital universitário

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 41, Issue 2, 2008, Pages 158-162

  Da Silva, Paulo Roberto ^a   Rabelo, Rosiley Aparecida De Souza ^a   Terra, Ana Paula Sarreta ^a   Teixeira, David Nascimento Silva ^a  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

Author keywords

Antifungal agents; Cryptococcosis; Cryptococcus gattii; Cryptococcus neoformans; Susceptibility

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; FUNGUS ISOLATION; HUMAN; INTRASPECIFIC VARIATION; MINIMUM INHIBITORY CONCENTRATION; UNIVERSITY HOSPITAL;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAZIL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; FLUCONAZOLE; HOSPITALS, UNIVERSITY; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MALE; MICROBIAL SENSITIVITY TESTS;

CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS;

EID: 45749090864     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822008000200005     Document Type: Article

References (27)

1. Baker DJ, Reboli AC. Images in clinical medicine: Cutaneous cryptococcosis. New England Journal of Medicine 336: 998, 1997.
2. Calhoun DL, Roberts GD, Galgiani JN, Bennett JE, Feingold DS, Jorgensen J, Kobayashi GS, Shadomy S. Results of survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin. Bangladesh Journal of Clinical Microbiology 23: 298-301, 1986.
3. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K. Australasian Cryptococcal Study Group Epidemiology and Host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clinical Infectious Diseases 31: 499-508, 2000.
4. Christensen WB. Urea decomposition as a means of differentiating Proteus and Paracolon cultures from each other and from salmonella and shigella types. Journal of Bacteriology 52: 461-466, 1946.
5. Colombo AL, Barchiesi F, Mcgough DA, Rinald MG. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. Journal of Clinical Microbiology 33: 535-540, 1995.
6. Diaz MR, Boekhout T, Theelen B, Fell JW. Molecular sequence analyses of the intergenic spacer (IGS) associated with rDNA of the two varieties of the pathogenic yeast, Cryptococcus neoformans. Systematic and Applied Microbiology 23: 535-545, 2000.
7. Ellis DH, Pfeiffer TJ. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 336: 923-925, 1990.
8. Fernandes OFL, Passos XS, Souza LK, Miranda AT, Cerqueira CH, Silva MR. In vitro susceptibility characteristics of Cryptococcus neoformans varieties from AIDS patients in Goiania. Memórias do Instituto Osvaldo Cruz 98: 839-841, 2003.
9. Franzot SP, Hamdan JS, Currie BP, Casadevall A. Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure. Journal of Clinical Microbiology 35: 2243-2251, 1997.
10. Fromtling RA, Bulmer GS. Distribution of Cryptococcus neoformans in a natural site. Infection and Immunity 31: 560-563, 1981.
11. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var gattii (serotypes B and C). Journal of Clinical Microbiology 15: 535-537, 1982.
12. Ministério da Saúde. Dados e Pesquisa em DST e Aids. Coordenação do programa nacional de DST/Aids. Boletim Epidemiológico.AIDS/Ministério da Saúde. Brasília, 2002.
13. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clinical Microbiology and Infection 8: 515-548, 1995.
14. Moraes EM, Prímola NS, Hamdan JS Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses 46:164-168, 2003.
15. Moreira TA, Ferreira MS, Ribas RM, Borges AS. Cryptococosis: clinical epidemiologycal laboratorial study and fungi varieties in 96 patients. Revista da Sociedade Brasileira de Medicina Tropical 39: 255-258, 2006.
16. National Committee for Clinical Laboratory Standards (NCCLS). Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA. 2002.
17. Nguyen MH, Yu CY. In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrobial Agents and Chemotherapy 42: 471-472, 1998.
18. Peachey PR, Gubbins PO, Martin RE. The association between cryptococcal variety and immunocompetent and immunocompromised hosts. Pharmacotherapy 18: 255-264, 1998.
19. Pedroso RS, Ferreira JC, Candido RC. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brazil. Memórias do Instituto Osvaldo Cruz 101: 239-243, 2006.
20. Perkins A, Gomez-Lopez, A, Mellado Rodriguez-Tudela EJL, Cuenca-Estrella M. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. Journal of Antimicrobial Chemotherapy 56: 1144-1147, 2005.
21. Pfaller MA, Boyken L, Hollis RJ, Messer AS, Tendolkar S, Diekema DJ. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. Journal of Clinical Microbiology 43: 3807-3810, 2005.
22. Rodriguez-Tudela JL, Berenguer Martiinez-Suarez JJ, Sanchez R. Comparison of a Spectrophotometric Microdilution Method with RPMI-2% Glucose with the National Committee for Clinical Laboratory Standards Reference Macrodilution Method M27-P for in vitro Susceptibility Testing of Amphotericin B, Flucytosine, and Fluconazole against Candida albicans Antimicrobial Agents And Chemotherapy 40: 1998-2003, 1996.
23. Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002. Journal of Antimicrobial Chemotherapy 54: 563-565, 2004.
24. Souza LKH, Fernandes OFL, Kobayashi CCBA, Passos XS, Costa CR, Lemos JA, Souza-Júnior AH, Silva MRR. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia City, Goiás, Brazil. Revista do Instituto de Medicina Tropical de São Paulo 47: 253-256, 2005.
25. Speed B, Dunt D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clinical Infectious Diseases 21: 28-34, 1995.
26. Staib F, Seibold M, Antweiler E, Fröhlich B, Weber S, Blisse A. The brown colour effect (BCE) of Cryptococcus neoformans in the diagnosis, control and epidemiology of Cryptococcus neoformans infections in AIDS patients. Zentralbl fur Bakteriologie, Mikrobiologie, und Hygiene Series A. 266: 167-177, 1987.
27. Trilles L, Fernández-Torres B, Lazéra MS, Wanke B, Guarro J. In vitro antifungal susceptibility of Cryptococcus gattii. Journal of Clinical Microbiology 42: 4815-4817, 2004.